Está por ver si la nueva variante evade suficientemente las vacunas.
Que el bicho va a seguir en 2023 es prácticamente seguro, pero la valoración de Moderna basa bastantes años de ingresos. Que con las de proteína llegando debería ver reducida su cuota de mercado.
Pero si de verdad hay variantes que evadan a todas las vacunas, las mRNA tienen ventaja.
What vaccine makers are saying about B.1.1.529 - now Omicron (cont):
-Novavax "has already initiated development of a new recombinant spike protein based on the known genetic sequence ... and will have it ready to begin testing and manufacturing within the next few weeks." (4/2)
In the European Union, the Qualified Person Responsible For Pharmacovigilance (QPPV) is an individual, usually an employee of a pharmaceutical company, who is personally responsible for the safety of the human pharmaceutical products marketed by that company in the EU. This function was established in 2004 by article 23 of regulation (EC) No 726/2004. The article establishes that the holder of a marketing authorization for a drug for human use must have a QPPV. When a company submits an application for permission to bring a medicinal product onto the market, the company submits a description of its system for monitoring the safety of the product in actual use (a pharmacovigilance system) and proof that the services of a QPPV are in place.[1]
"The holder of an authorisation for a medicinal product for human use granted in accordance with the provisions of this Regulation shall have permanently and continuously at his disposal an appropriately qualified person responsible for pharmacovigilance."
#20593
Re: Novavax (NVAX): Un Nuevo Comienzo
Según leo la virulencia es leve/muy leve. Muy posible corrección lunes a zona 200.